title: Three cases of thyroid cancer following the diagnosis of testicular cancer: treatment-related complication or genetics?
abstract: Large-scale epidemiological studies have shown that the incidence of second primary thyroid cancer in subjects diagnosed and treated for testicular cancer is raised. This finding is strongly associated to treatment with radiotherapy and/or chemotherapy and it is explained by their mutagenic effect. On the other hand, inherited cancer susceptibility syndromes inducing both testicular and thyroid cancers denote that these tumours might share common genomic aberrations. We herein present our experience with three cases of metachronous development of thyroid cancer after diagnosis and treatment of testicular cancer in our tertiary cancer centre. Our case report contributes to the limited available literature on such findings and aims to raise awareness of the cancer physicians treating these particular tumour types.
authors.affiliation: MBBS, MRCP, MSc, Department of Medical Oncology, Beatson West of Scotland Cancer Centre, Glasgow, UK Pavlina.Spiliopoulou@nhs.net.
authors.forename: Pavlina
authors.initials: P
authors.lastname: Spiliopoulou
authors.affiliation: MBChB, University of Glasgow, School of Medicine, Glasgow, UK.
authors.forename: Sarah Pauline
authors.initials: SP
authors.lastname: Bowers
authors.affiliation: MSc, Department of Clinical Genetics, Southern General Hospital, Glasgow, UK.
authors.forename: Sarah
authors.initials: S
authors.lastname: Gibson
authors.affiliation: MBChB, DM, FRCP, Department of Medical Oncology, Beatson West of Scotland Cancer Centre, Glasgow, UK.
authors.forename: Jeff
authors.initials: J
authors.lastname: White
authors.affiliation: Professor, MBChB, FRCR, Department of Medical Oncology, Beatson West of Scotland Cancer Centre, Glasgow, UK.
authors.forename: Nick
authors.initials: N
authors.lastname: Reed
mesh_terms: D000328:Adult; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000008:administration & dosage; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols; D001761:Bleomycin / Q000008:administration & dosage; D002173:Cancer Care Facilities; D002277:Carcinoma / Q000175:diagnosis / Q000209:etiology* / Q000601:surgery; D002291:Carcinoma, Papillary; D002945:Cisplatin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D006801:Humans; D008297:Male; D008499:Medical Records; D016609:Neoplasms, Second Primary / Q000175:diagnosis / Q000209:etiology* / Q000473:pathology; D051059:PTEN Phosphohydrolase / Q000235:genetics; D012606:Scotland; D062606:Tertiary Care Centers; D013736:Testicular Neoplasms / Q000150:complications / Q000188:drug therapy; D000077273:Thyroid Cancer, Papillary; D013964:Thyroid Neoplasms / Q000175:diagnosis / Q000209:etiology* / Q000473:pathology / Q000601:surgery
chemical_list: D000903:Antibiotics, Antineoplastic; D000970:Antineoplastic Agents; D000972:Antineoplastic Agents, Phytogenic; D001761:Bleomycin; D005047:Etoposide; D051059:PTEN Phosphohydrolase; C494929:PTEN protein, human; D002945:Cisplatin
keywords: Testicular cancer; chemotherapy; genetics; radiotherapy; thyroid cancer